bluebird bio announces key leadership and board appointments and upcoming investor events

0

CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –bluebird bio, Inc. (NASDAQ: BLUE) today announced key leadership and board appointments ahead of the company’s planned separation, slated for mid-October 2021. The company also outlined plans for events for the investors and participation in investor conferences leading to the separation.

“As we approach separation, we strive to ensure that bluebird organic and 2seventy organic have strong management teams and boards of directors to lead each company through its next phase,” said Nick Leschly, Chief Executive Officer. bluebird. “After an intense period of internal work to prepare for the separation, we now look forward to engaging with key external stakeholders to share each company’s plans as we approach our target October separation.”

update of biological management of blue birds

“I am delighted to welcome Gina Consylman to the management team of bluebird bio. Upon the effectiveness of the planned separation, Gina will become the CFO of bluebird bio, ”said Andrew Obenshain, President, Serious Genetic Diseases. “Her previous experience in a similar spin-off operation and helping lead a successful business organization through times of change has already made her an invaluable partner as we go through an important execution phase at bluebird. ”

Gina Consylman joined bluebird in August 2021 as CFO of the Critical Genetic Diseases business, overseeing finance, tax, accounting, treasury, insurance and investor relations. She has over 25 years of experience in finance, investor relations, strategy and business development. Prior to joining bluebird, she was Senior Vice President and Chief Financial Officer at Ironwood Pharmaceuticals. Prior to Ironwood, Gina was Vice President, Corporate Controller and Senior Accountant at Analogic Corporation, a public health and safety technology solutions company, where she oversaw the company’s global accounting and treasury teams. Prior to working at Analogic, Gina held the position of Senior Manager, Corporate Accounting at Biogen Inc., where she led the accounting teams of the US corporate and commercial business units.

Gina sits on the board of directors of Assembly Biosciences, Inc. and Verastem Oncology. Chartered Accountant, Gina began her career in public accounting at Ernst & Young LLP. She holds a BS in Accounting from Johnson & Wales University and an MS in Taxation from Bentley University.

bluebird bio board update

“As the launch of 2seventy bio approaches, I am delighted to welcome Marcela Maus to the board of directors of bluebird bio. As soon as the planned separation takes effect, Marcela will join the board of directors of 2seventy bio, ”said Nick Leschly. “Marcela’s work as a translational physician-researcher in the field of immunology, particularly with regard to T cell immunotherapies and cell therapies in cancer treatment, makes her ideal for providing valuable information to the 2seventy team. ”

Marcela Maus, MD, Ph.D., is currently Associate Professor at Harvard Medical School, Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at the Mass General Cancer Center, as well as attending physician in transplant surgery. hematopoietic cells and cell therapy division of oncology at the Mass General Cancer Center. She is an associate member of the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT) and an associate member of the Ragon Institute of Mass General Cancer Center, MIT and Harvard. Dr. Maus’ lab focuses on the biology of human T cell activation, costimulation and memory, as well as the application of human T cell therapies to human diseases, including forward and reverse translation. modified T cell therapies in early phase clinical trials.

Dr Maus completed undergraduate studies at MIT and holds graduate degrees (MD, Ph.D.) from the University of Pennsylvania. Dr Maus was trained in Internal Medicine at the University of Pennsylvania and Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, is board certified in all three disciplines, and practices medical oncology. She also sits on several scientific and clinical advisory boards for the biotechnology industry as well as external academic medical centers.

Upcoming investor events

The members of the management teams of bluebird bio and 2seventy bio will participate in the following upcoming investor conferences:

  • Morgan Stanley 19e Annual Health Conference

    • bio bluebird: September 10, 2021 at 10:15 a.m.ET

    • Biography of 2seventy: September 9, 2021 at 12:30 p.m. ET

  • Bank of America Global Healthcare Conference 2021

    • bio bluebird: September 16, 2021 at 9:10 a.m.ET

    • Biography of 2seventy: September 17, 2021 at 10:05 am ET

About bluebird bio, Inc.

bluebird bio is a pioneer in gene therapy for a specific purpose. From our head office in Cambridge, MA, we develop gene and cell therapies for serious genetic diseases and cancer, with the goal that people facing life-threatening conditions with limited treatment options can live their lives to the fullest. . Beyond our laboratories, we work to positively disrupt the health system to create access, transparency and education so that gene therapy can become accessible to all who can benefit from it.

bluebird bio is a human enterprise fueled by human stories. We put our care and expertise at the service of a wide range of disorders: cerebral adrenoleukodystrophy, sickle cell anemia, -thalassemia and multiple myeloma, using gene and cell therapy technologies, including gene addition and gene editing. (activated by megaTAL).

bluebird bio has additional nests in Seattle, Washington; Durham, North Carolina; and Zug, Switzerland. For more information visit bluebirdbio.com.

Follow bluebird’s bio on social media: @bluebirdbio, LinkedIn, Instagram and Youtube.

bluebird bio, 2seventy and 2seventy bio are registered trademarks of bluebird bio, Inc.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the financial condition of the company, results of operations, as well as statements concerning the plans and expectations of the company for operations, including timing, leadership, structure, including the allocation of assets between bluebird bio and 2seventy bio, and the impact of a separation; as well as the company’s intention to provide further updates on the separation and related fundraising strategies for bluebird bio and 2seventy. All forward-looking statements are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those stated or implied. by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that we may not complete the separation on the terms or schedule currently contemplated, if any, achieve the expected benefits of a separation, and a separation could adversely affect to our company, the results of operations and financial position; the risk that the transaction is not exempt from tax; we may not be able to make, in a timely or cost effective manner, the changes necessary to operate as independent businesses; 2 Seventy bio’s lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet financial reporting and other operating requirements. as an independent public enterprise; dedicated financial and / or strategic sources of funding may not be available on favorable terms; a separation or an announcement thereof may have a negative impact on our ability to attract or retain key personnel; a separation may have a negative impact on the effectiveness of development and marketing efforts on the part of us and that of our partners; our business may be disrupted as a result of the announcement or expectation of separation; and the risk that we may not be able to realize the expected benefits of resizing and restructuring our workforce. For a discussion of other risks and uncertainties, and other important factors, each of which could cause our actual results to differ from those contained in forward-looking statements, see the section entitled “Risk Factors” in our Form 10 -Q most recent. , as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of publication, and bluebird bio makes no commitment to update such information, except as required by law.



Source link

Leave A Reply

Your email address will not be published.